- Home
- BUD vs GILD Comparison
BUD vs GILD Comparison
Compare BUD & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BUD
- GILD
- Stock Information
- Founded
- BUD 1366
- GILD 1987
- Country
- BUD Belgium
- GILD United States
- Employees
- BUD N/A
- GILD N/A
- Industry
- BUD Beverages (Production/Distribution)
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BUD Consumer Staples
- GILD Health Care
- Exchange
- BUD Nasdaq
- GILD Nasdaq
- Market Cap
- BUD 121.9B
- GILD 131.5B
- IPO Year
- BUD N/A
- GILD 1992
- Fundamental
- Price
- BUD $65.01
- GILD $103.17
- Analyst Decision
- BUD Buy
- GILD Buy
- Analyst Count
- BUD 3
- GILD 26
- Target Price
- BUD $64.00
- GILD $108.00
- AVG Volume (30 Days)
- BUD 2.9M
- GILD 9.5M
- Earning Date
- BUD 05-07-2025
- GILD 04-24-2025
- Dividend Yield
- BUD 1.59%
- GILD 3.06%
- EPS Growth
- BUD 10.00
- GILD 1118.07
- EPS
- BUD 2.86
- GILD 4.73
- Revenue
- BUD $59,768,000,000.00
- GILD $28,735,000,000.00
- Revenue This Year
- BUD $1.64
- GILD $1.88
- Revenue Next Year
- BUD $4.53
- GILD $3.95
- P/E Ratio
- BUD $23.02
- GILD $21.81
- Revenue Growth
- BUD 0.65
- GILD 4.68
- 52 Week Low
- BUD $45.94
- GILD $62.07
- 52 Week High
- BUD $67.49
- GILD $119.96
- Technical
- Relative Strength Index (RSI)
- BUD 60.07
- GILD 41.05
- Support Level
- BUD $65.14
- GILD $99.32
- Resistance Level
- BUD $66.38
- GILD $107.56
- Average True Range (ATR)
- BUD 1.27
- GILD 4.58
- MACD
- BUD 0.21
- GILD -0.09
- Stochastic Oscillator
- BUD 76.44
- GILD 62.70
About BUD Anheuser-Busch Inbev SA Sponsored ADR (Belgium)
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. The company's portfolio contains six of the top 10 beer brands by volume, according to Euromonitor, and we estimate it distributes 23 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and US-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev, an 87% stake in Budweiser APAC, and in 2016 it acquired SABMiller.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).